Kong GM, Zhang XR, Wu KY, Zhao FY, Zhu HH, Zhang XD, Liao YX, Bo P. Inhibitory effect of KDR-specific monoclonal antibody on tumor growth in nude mice bearing human gastric cancer.
Shijie Huaren Xiaohua Zazhi 2011;
19:2925-2930. [DOI:
10.11569/wcjd.v19.i28.2925]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To evaluate the anti-cancer activity of monoclonal antibody (mA) against vascular endothelial growth factor (VEGF) receptor II (KDR) in nude mice bearing human gastric cancer.
METHODS: BALB/c nude mice were subcutaneously inoculated with human gastric cancer cells (SGC-7901) to develop a xenograft model of human gastric cancer. When tumor volume reached 100-300 mm3, all mice were randomly divided into three groups and intraperitoneally injected with KDR-mAb, 5-FU and physiological saline, respectively. Ten days after injection, all tumors were removed, measured, and weighted. The reduced rate of tumor growth was calculated. VEGF expression was quantified by real-time polymerase chain reaction (PCR) and immunohistochemistry.
RESULTS: KDR-mAb inhibited the growth of solid tumors compared to the two control groups (1889.94 mm3 ± 396.64 mm3vs 9398.34 mm3± 7413.96 mm3, 1.07 g± 0.58 g vs 1.68 g± 0.18 g, both P < 0. 05), and the reduced rate of tumor growth was up to 36. 3%. VEGF expression was significantly inhibited in tumors in the KDR-mAb treated group (P < 0. 05).
CONCLUSION: KDR-mAb can inhibit the growth of solid tumors in a mouse xenograft model of gastric cancer and may be used for clinical treatment of human gastric cancer.
Collapse